BEAM Beam Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1745999 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY163.3%
TTM net income YoY74.1%
TTM EPS YoY80.0%
Revenue 3-yr CAGR21.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-267.7%
Net margin-73.0%
FCF margin-271.6%
EBITDA margin-252.6%
Returns
ROE-11.1%
ROA-8.3%
ROIC (approx.)-40.2%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets24.9%
Debt / equity0.11x
Current ratio13.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.63x
Accruals ratio21.8%
Payout ratio—
Capex / revenue6.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $139.74M | $63.52M | $377.71M | $60.92M | $51.84M |
| R&D expense | $409.62M | $367.56M | $437.38M | $311.59M | $387.09M |
| SG&A expense | $113.82M | $111.53M | $116.81M | $87.81M | $57.22M |
| Operating income | -$383.69M | -$415.57M | -$176.49M | -$338.48M | -$392.46M |
| Pretax income | -$79.99M | -$376.70M | -$131.16M | -$260.18M | -$370.64M |
| Income tax | $0 | $39,000 | $1.37M | $3.41M | $0 |
| Net income | -$79.99M | -$376.74M | -$132.53M | -$289.09M | -$370.64M |
| EBITDA | -$361.40M | -$393.64M | -$156.47M | -$324.33M | -$385.01M |
| EPS (basic) | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 |
| EPS (diluted) | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 |
| Weighted avg. shares (diluted) | 98.91M | 82.31M | 77.15M | 70.02M | 64.23M |
| Balance sheet | |||||
| Cash & equivalents | $294.94M | $290.11M | $435.89M | $245.52M | $572.74M |
| Short-term investments | $950.27M | $568.77M | $753.98M | $845.37M | — |
| Current assets | $1.27B | $878.15M | $1.21B | $1.09B | $1.27B |
| PP&E, net | $104.50M | $111.41M | $124.96M | $115.62M | $84.26M |
| Total assets | $1.48B | $1.10B | $1.46B | $1.34B | $1.47B |
| Current liabilities | $96.94M | $182.07M | $205.56M | $223.59M | $213.44M |
| Total liabilities | $242.82M | $370.28M | $478.38M | $608.24M | $647.72M |
| Shareholders' equity | $1.24B | $733.54M | $981.33M | $733.47M | $826.74M |
| Shares outstanding | 101.75M | 83.63M | 81.63M | 71.28M | 68.39M |
| Cash flow statement | |||||
| Operating cash flow | -$345.10M | -$347.25M | -$149.19M | $22.53M | -$66.27M |
| Capital expenditure | $14.95M | $8.95M | $33.73M | $48.95M | $46.81M |
| Free cash flow | -$360.05M | -$356.19M | -$182.93M | -$26.42M | -$113.08M |
| Investing cash flow | -$121.44M | $185.01M | $71.84M | -$461.34M | -$294.14M |
| Financing cash flow | $478.05M | $7.74M | $276.45M | $111.59M | $756.14M |
| Depreciation & amortization | $22.29M | $21.93M | $20.01M | $14.15M | $7.45M |
| Stock-based compensation | $94.24M | $120.66M | $98.65M | $84.32M | $43.57M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.